Company Overview and News

 
[Press] Empyrean Energy Final Results: The Company Is Excited About Stronger Oil Prices and Three Projects in Development

2018-08-07 oilvoice
Empyrean Energy is pleased to announce its final results for the year ended 31 March 2018. The full Report and Accounts will be made available on the Company's website in the coming days.
MBL MALRY CHOLY 2883 CHOLF MALRF EME MIN CEO

 
[Press] Empyrean Energy Final Results: the Company is excited about stronger oil prices and three projects in development

2018-08-07 oilvoice
Empyrean Energy is pleased to announce its final results for the year ended 31 March 2018. The full Report and Accounts will be made available on the Company's website in the coming days.
MBL MALRY CHOLY 2883 CHOLF MALRF EME MIN CEO

 
Core Labs (CLB) Slashes Q2 Guidance, Shares Plunge 13.6%

2018-07-03 zacks
Core Laboratories N.V.’s (CLB - Free Report) shares declined more than 13.5% to eventually close at $112.66 on Jul 2, after the company downwardly revised its second-quarter 2018 outlook amid deferred international activities. In its first-quarter report, the company forecast second-quarter earnings of around 64-68 cents per share. However, a delay in the recovery of international oilfield development activities has compelled the company to cut its guidance.
ABX CHOLY EMES AROC 2883 CHOLF CLB ABX

 
PetroChina lifts Hong Kong stocks to biggest two-week gain on gas price increase

2018-05-28 scmp
China’s largest producer of oil and gas contributed to almost 13 per cent of the gain on the Hang Seng Index
0168 XNGSF CGASY XNGSY CHOLY 2883 CHOLF

46
[Press] Middle East Oilfield Services Market - Analysis of Growth, Trends and Forecasts (2018 - 2023)

2018-04-12 oilvoice - 1
The Middle East produces more than 30% of the crude oil produced globally, and had 385 drilling rigs in October 2017. After the crude oil price started increasing in the second half of 2016, the oil & gas activity in the region started stabilizing slowly. In November 2017, crude oil price crossed USD 60 barrel mark. The region is expected to witness an increase in oil & gas activity in 2018, with Saudi Arabia being the leader, and Iran and Iraq to register a high growth rate.
BHI SLB ESV TKPPY WFT SPMI CHOLY 2883 CHOLF SCL SLB NBR

 
[Press] Ashurst Advises on the Sale of a 50% Stake in Barryroe Field in Ireland

2018-03-28 oilvoice
International law firm Ashurst is advising Providence Resources plc ('Providence'), the Irish based oil & gas exploration company, and Lansdowne Oil and Gas plc on a farm-out agreement ('FOA') with APEC Energy Enterprises Limited ('APEC') relating to standard exploration licence ('SEL') 1/11, containing the Barryroe Field. SEL 1/11 is owned by EXOLA DAC ('EXOLA') (80%), a wholly-owned Providence subsidiary, and Lansdowne Celtic Sea Limited (20%), collectively the 'Barryroe Partners'.
PVDRF PVRS CHOLY PVR 2883 CHOLF

41
[Press] Oilfield Services Market is Set for a Rapid Growth and is Expected to Reach USD 127.31 Billion by 2022

2018-03-28 oilvoice
Zion Market Research has published a new report titled “Oilfield Services Market (Pressure Pumping Services, Oil Country Tubular Goods, Wireline Services, Well Completion Equipment & Services, Well Intervention Services, Drilling & Completion Fluid Services, and Coiled Tubing Services) for Offshore and Onshore Applications: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022”.
BHI SLB SPN NOV WFT CHOLY 2883 CHOLF SCL SLB

 
[Press] Providence Resources Barryroe Farm-out

2018-03-28 oilvoice
Dublin and London – March 28, 2018 - Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Oil & Gas Exploration Company (“Providence” or the “Company”), today provides a commercial update on Standard Exploration Licence (“SEL”) 1/11 that contains the Barryroe oil accumulation. SEL 1/11 is operated by EXOLA DAC (“EXOLA”)(80%), a wholly-owned Providence subsidiary, on behalf of its partner Lansdowne Celtic Sea Limited (“Lansdowne”)(20%), collectively referred to as the “Barryroe Partners”.
CHOLY 2883 CHOLF

2
Providence Resources P.l.c. - Farm-out Agreement Signed - Standard Exploration Licence 1/11 - Barryroe, North Celtic Sea Basin

2018-03-28 globenewswire
Dublin and London - March 28, 2018 - Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Oil & Gas Exploration Company ("Providence" or the "Company"), today provides a commercial update on Standard Exploration Licence ("SEL") 1/11 that contains the Barryroe oil accumulation. SEL 1/11 is operated by EXOLA DAC ("EXOLA")(80%), a wholly-owned Providence subsidiary, on behalf of its partner Lansdowne Celtic Sea Limited ("Lansdowne")(20%), collectively referred to as the "Barryroe Partners".
CHOLY LNSTY 2883 MRO CHOLF MIOI

42
[Press] Oilfield Services Market - Evolving Industry Trends and Key Insights by 2022

2018-03-20 oilvoice - 1
Zion Market Research has published a new report titled “Oilfield Services Market (Pressure Pumping Services, Oil Country Tubular Goods, Wireline Services, Well Completion Equipment & Services, Well Intervention Services, Drilling & Completion Fluid Services, and Coiled Tubing Services) for Offshore and Onshore Applications: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022”.
BHI SLB SPN NOV WFT CHOLY 2883 CHOLF SCL SLB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...